FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130036268> ?p ?o ?g. }

• W2130036268 endingPage "384" @default.
• W2130036268 startingPage "377" @default.
• W2130036268 abstract "The National Institute of Neurological Disorders and Stroke (NINDS) Recombinant Tissue Plasminogen Activator (rtPA) Stroke Study demonstrated a clinically meaningful and statistically significant benefit of tissue plasminogen activator (tPA). Adjusting for the baseline National Institutes of Health (NIH) Stroke Scale, the benefit of tPA remained. However, other authors suggest that an imbalance in baseline stroke severity between the tPA and placebo groups confounded the results. Another issue that has been raised concerns a possible increase in early mortality for individuals given tPA. In post hoc subgroup analysis, we describe the effect of tPA across a spectrum of time from stroke onset to treatment and stroke severity subgroups. Stroke severity was based on the NIH Stroke Scale. We also compare early mortality (2-week and 30-day) in the tPA and placebo groups.Using combined data from the 2 NINDS rtPA Stroke Study trials, we performed post hoc subgroup analyses of 3-month favorable outcome (defined by the NIH Stroke Scale, Barthel, Rankin, and Glasgow Outcome Scales). We categorized patients from the trials into onset to treatment (0 to 90 minutes, 91 to 180 minutes) by NIH Stroke Scale (< or =5, 6 to 20, >20) subgroups. Analyses were adjusted for all variables previously shown to be associated with favorable outcome at 3 months. We also compared early mortality within onset-to-treatment subgroups.For all the 12 specified onset-to-treatment-NIH Stroke Scale subgroups, the adjusted odds ratio for a favorable 3-month outcome was greater than 1.0 and favored tPA. We detected no difference in mortality between patients treated with rtPA and those treated with placebo by 2 weeks posttreatment (rtPA=9%, placebo=13%; P =.49) or by 30 days (rtPA=11%, placebo=16%; P =.30).These are descriptive post hoc subgroup analyses. Using cut points defined in previous critiques of the NINDS trials, these analyses give results consistent with previous NINDS Study Group reports. Baseline NIH Stroke Scale imbalance does not account for the better outcome of rtPA-treated patients." @default.
• W2130036268 created "2016-06-24" @default.
• W2130036268 creator A5006049935 @default.
• W2130036268 creator A5010431596 @default.
• W2130036268 creator A5026886390 @default.
• W2130036268 creator A5033945043 @default.
• W2130036268 creator A5047486922 @default.
• W2130036268 creator A5077001256 @default.
• W2130036268 creator A5086474167 @default.
• W2130036268 creator A5090972492 @default.
• W2130036268 date "2005-04-01" @default.
• W2130036268 modified "2023-09-26" @default.
• W2130036268 title "The Impact of Imbalances in Baseline Stroke Severity on Outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study" @default.
• W2130036268 cites W1964052017 @default.
• W2130036268 cites W1978136073 @default.
• W2130036268 cites W1982533446 @default.
• W2130036268 cites W2027123157 @default.
• W2130036268 cites W2049777870 @default.
• W2130036268 cites W2070688896 @default.
• W2130036268 cites W2078110114 @default.
• W2130036268 cites W2155758555 @default.
• W2130036268 cites W2292308933 @default.
• W2130036268 cites W2341972145 @default.
• W2130036268 cites W2407262228 @default.
• W2130036268 cites W3208775091 @default.
• W2130036268 doi "https://doi.org/10.1016/j.annemergmed.2004.06.021" @default.
• W2130036268 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15795715" @default.
• W2130036268 hasPublicationYear "2005" @default.
• W2130036268 type Work @default.
• W2130036268 sameAs 2130036268 @default.
• W2130036268 citedByCount "51" @default.
• W2130036268 countsByYear W21300362682013 @default.
• W2130036268 countsByYear W21300362682014 @default.
• W2130036268 countsByYear W21300362682015 @default.
• W2130036268 countsByYear W21300362682016 @default.
• W2130036268 countsByYear W21300362682017 @default.
• W2130036268 countsByYear W21300362682018 @default.
• W2130036268 countsByYear W21300362682019 @default.
• W2130036268 countsByYear W21300362682022 @default.
• W2130036268 crossrefType "journal-article" @default.
• W2130036268 hasAuthorship W2130036268A5006049935 @default.
• W2130036268 hasAuthorship W2130036268A5010431596 @default.
• W2130036268 hasAuthorship W2130036268A5026886390 @default.
• W2130036268 hasAuthorship W2130036268A5033945043 @default.
• W2130036268 hasAuthorship W2130036268A5047486922 @default.
• W2130036268 hasAuthorship W2130036268A5077001256 @default.
• W2130036268 hasAuthorship W2130036268A5086474167 @default.
• W2130036268 hasAuthorship W2130036268A5090972492 @default.
• W2130036268 hasConcept C126322002 @default.
• W2130036268 hasConcept C127413603 @default.
• W2130036268 hasConcept C142724271 @default.
• W2130036268 hasConcept C156957248 @default.
• W2130036268 hasConcept C1862650 @default.
• W2130036268 hasConcept C204787440 @default.
• W2130036268 hasConcept C27081682 @default.
• W2130036268 hasConcept C2776572282 @default.
• W2130036268 hasConcept C2779581417 @default.
• W2130036268 hasConcept C2780645631 @default.
• W2130036268 hasConcept C2780931571 @default.
• W2130036268 hasConcept C2909817843 @default.
• W2130036268 hasConcept C3020199598 @default.
• W2130036268 hasConcept C500558357 @default.
• W2130036268 hasConcept C535046627 @default.
• W2130036268 hasConcept C541997718 @default.
• W2130036268 hasConcept C67761136 @default.
• W2130036268 hasConcept C71924100 @default.
• W2130036268 hasConcept C78519656 @default.
• W2130036268 hasConceptScore W2130036268C126322002 @default.
• W2130036268 hasConceptScore W2130036268C127413603 @default.
• W2130036268 hasConceptScore W2130036268C142724271 @default.
• W2130036268 hasConceptScore W2130036268C156957248 @default.
• W2130036268 hasConceptScore W2130036268C1862650 @default.
• W2130036268 hasConceptScore W2130036268C204787440 @default.
• W2130036268 hasConceptScore W2130036268C27081682 @default.
• W2130036268 hasConceptScore W2130036268C2776572282 @default.
• W2130036268 hasConceptScore W2130036268C2779581417 @default.
• W2130036268 hasConceptScore W2130036268C2780645631 @default.
• W2130036268 hasConceptScore W2130036268C2780931571 @default.
• W2130036268 hasConceptScore W2130036268C2909817843 @default.
• W2130036268 hasConceptScore W2130036268C3020199598 @default.
• W2130036268 hasConceptScore W2130036268C500558357 @default.
• W2130036268 hasConceptScore W2130036268C535046627 @default.
• W2130036268 hasConceptScore W2130036268C541997718 @default.
• W2130036268 hasConceptScore W2130036268C67761136 @default.
• W2130036268 hasConceptScore W2130036268C71924100 @default.
• W2130036268 hasConceptScore W2130036268C78519656 @default.
• W2130036268 hasIssue "4" @default.
• W2130036268 hasLocation W21300362681 @default.
• W2130036268 hasLocation W21300362682 @default.
• W2130036268 hasOpenAccess W2130036268 @default.
• W2130036268 hasPrimaryLocation W21300362681 @default.
• W2130036268 hasRelatedWork W2130036268 @default.
• W2130036268 hasRelatedWork W2171891409 @default.
• W2130036268 hasRelatedWork W2328015176 @default.
• W2130036268 hasRelatedWork W2576973703 @default.
• W2130036268 hasRelatedWork W2617664251 @default.
• W2130036268 hasRelatedWork W2807282135 @default.
• W2130036268 hasRelatedWork W2885966173 @default.

• next